Clinical molecular pathology analysis has become an indispensable laboratory tool that can be used to characterise tumour biology and drive therapeutic decisions.[1] Could genetic testing help you get a clear picture of what’s potentially driving tumour growth in your patients?[1][2][3]
The potential benefits of routine genetic sequencing in metastatic tumours are recognised by guidelines[2][4]
Common tests used to detect genetic alterations include both NGS and real-time polymerase chain reaction (PCR)[7]
Test for genetic alterations to ensure you have the information needed to facilitate treatment decision-making[4]
The management of UC is becoming multidisciplinary, with close cooperation and critical input needed from different specialities to provide effective disease management plans for patients[13][14]
Your pathologist is vital in helping you to tailor your management approach to your patient’s tumour:[15]
When establishing testing protocols, it is important to liaise with the treating urologist to ensure sufficient sample quality is available:[7][8][9][11][16][17]
Learn more about FGFR alterations in oncology and their importance in UC: